Patents Assigned to Bristol-Meyers Squibb Company
  • Patent number: 10287295
    Abstract: Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R? are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-?, and can be used to treat disease by blocking TGF-? signaling.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: May 14, 2019
    Assignees: Rigel Pharmaceuticals, Inc., Bristol-Meyers Squibb Company
    Inventors: Todd Kinsella, Marina Gelman, Hui Hong, Ihab S. Darwish, Rajinder Singh, Jiaxin Yu, Robert M. Borzilleri, Upender Velaparthi, Peiying Liu, Chetan Padmakar Darne, Hasibur Rahaman, Jayakumar Sankara Warrier
  • Publication number: 20180244671
    Abstract: The present invention provides compounds of Formula (I): wherein A, Y and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Application
    Filed: August 30, 2016
    Publication date: August 30, 2018
    Applicant: Bristol-Meyers Squibb Company
    Inventors: Andrew Quoc Viet, Nicholas Ronald Wurtz, Scott A. Shaw, Ellen K. Kick, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty
  • Patent number: 9840511
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: formula (I).
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: December 12, 2017
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow
  • Patent number: 9822112
    Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: November 21, 2017
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Ivar M. McDonald, Naidu S. Chowdari, Walter Lewis Johnson, Yong Zhang, Robert M. Borzilleri, Sanjeev Gangwar
  • Publication number: 20170217930
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Application
    Filed: May 6, 2015
    Publication date: August 3, 2017
    Applicant: Bristol-Meyers Squibb Company
    Inventor: Chongqing Sun
  • Patent number: 9580420
    Abstract: A process is provided for preparing 4-(8-(2-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)bicyclo[2.2.1]heptan-1-ol and novel intermediates used in the process. The compound is a 11-beta hydroxysteroid dehydrogenase type I inhibitor which exhibits activity in the treatment of various metabolic diseases.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: February 28, 2017
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Xinhua Qian, Keming Zhu, Joerg Deerberg, Wendy Wangying Yang, Kana Yamamoto, Matthew R. Hickey
  • Publication number: 20160332985
    Abstract: The present disclosure is generally directed to compounds of formula (I) which can inhibit AAKI (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKI.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 17, 2016
    Applicant: Bristol-Meyers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, John E. Macor, Joanne J. Bronson, Bireshwar Dasgupta, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • Publication number: 20160016910
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 21, 2016
    Applicant: Bristol-Meyers Squibb Company
    Inventors: Mimi L. Quan, Zilun Hu, Cailan Wang, Peter W. Glunz
  • Patent number: 9193725
    Abstract: Compounds of Formula I are provided, including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: wherein Z is selected from the group consisting of: which are useful as HIV attachment inhibitors.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 24, 2015
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Tao Wang, John F. Kadow, Nicholas A. Meanwell, Lawrence G. Hamann
  • Patent number: 9133160
    Abstract: Disclosed are heteroaryl compounds of Formula (I), (I), or pharmaceutically acceptable salts thereof, wherein Z is CH or N; W is CR3 or N; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 15, 2015
    Assignee: Bristol-Meyers Squibb Company
    Inventor: Audris Huang
  • Publication number: 20150246930
    Abstract: Disclosed are compounds of Formula (I), wherein: X is O or —NR3; R1 is —CH2CH2CH3, —CH2CF3, —CH2CH2CF3, —CH2CF2CH3, —CH2CH2CH2CF3, —CH2CH2CF2CH3, —CH2CH(CH3)CF3, —CH2CH2CH2F, or CH2(cyclopropyl); R2 is —CH2CH2CH3, —CH2CF3, —CH2CH2CF3, —CH2CF2CH3, —CH2CH2CH2CF3, —CH2CH2CH2F, —CH2CH(CH3)CF3, CH2CH2CF2CH3, —CH2(cyclopropyl), —CH(CH3)(cyclopropyl), phenyl, fluorophenyl, chlorophenyl, trifluorophenyl, methylisoxazolyl, pyridinyl, formula (i), formula (ii), formula (iii), formula (iv) or formula (v); Ring A is phenyl or pyridinyl; and R3, Ra, Rb, Rc, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Application
    Filed: September 20, 2013
    Publication date: September 3, 2015
    Applicant: Bristol-Meyers Squibb Company
    Inventors: Weifang Shan, Ashvinikumar V. Gavai, James Aaron Balog
  • Publication number: 20130231354
    Abstract: Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: Q is: (i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or (ii) 9- to 10-membered bicyclic heteroaryl selected from Formula (II) and; wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; and R1, R2, R3, and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: November 9, 2011
    Publication date: September 5, 2013
    Applicant: Bristol-Meyers Squibb Company
    Inventors: Joel F. Austin, David B. Frennesson, Mark G. Saulnier
  • Patent number: 8513428
    Abstract: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: August 20, 2013
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Soojin Kim, Bruce T. Lotz, Mary F. Malley, Jack Z. Gougoutas, Martha Davidovich, Sushil K. Srivastava
  • Patent number: 8470854
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: June 25, 2013
    Assignee: Bristol-Meyers Squibb Company
    Inventor: Donald J. P. Pinto
  • Patent number: 8454959
    Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: June 4, 2013
    Assignees: Bristol-Meyers Squibb Company, Domantis Limited
    Inventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
  • Patent number: 8404672
    Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R1 is cycloalkyl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as vascular disease and autoimmune diseases.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: March 26, 2013
    Assignee: Bristol-Meyers Squibb Company
    Inventors: William J. Pitts, Alaric J. Dyckman, Steven H. Spergel, Scott Hunter Watterson
  • Patent number: 8383821
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: February 26, 2013
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Andrew P. Degnan, Kevin W. Gillman, Derek J. Denhart, Jonathan L. Ditta, Ramkumar Rajamani, Ying Han, George O. Tora
  • Patent number: 8354410
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: January 15, 2013
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, John F. Kadow
  • Patent number: 8273777
    Abstract: Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure where Q is and R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: September 25, 2012
    Assignee: Bristol-Meyer Squibb Company
    Inventors: Yan Shi, Peter T. W. Cheng, Ying Wang, Denis E. Ryono
  • Patent number: 8202881
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: June 19, 2012
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Ashok V. Purandare, James W. Grebinski, Amy Hart, Jennifer Inghrim, Gretchen Schroeder, Honghe Wan